A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
Clinical trial NCT07000149 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07000149
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-28
- Primary completion
- 2027-01-29
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.